New Two-Pronged attack on Tough-to-Treat blood cancers
NCT ID NCT07077512
Summary
This study is testing a two-part treatment for B-cell lymphoma that has come back or not responded to other therapies. First, doctors modify a patient's own immune cells (CAR-T cells) to attack the cancer. Then, they add an immunotherapy drug (sintilimab) for up to a year to help keep the cancer away. The main goal is to see how many patients achieve a complete disappearance of their cancer three months after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA ( FL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fifth Affiliated Hospital of Guangzhou Medical University
NOT_YET_RECRUITINGGuangzhou, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangzhou overseas Chinese hospital
NOT_YET_RECRUITINGGuangzhou, 510632, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun Yat-sen Universitiy Cancer Center
RECRUITINGGuangzhou, 51000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.